The European Medicines Agency (EMA) has expressed support for the provisional agreement reached by the European Parliament and the Council of the European Union regarding the proposed Critical Medicines Act (CMA). This legislative framework aims to enhance the resilience and security of supply chains for critical medicines, which is increasingly vital in the face of global disruptions that threaten public health across the EU.
In recent years, EU Member States have grappled with significant medicine shortages, exacerbated by challenges such as the COVID-19 pandemic and ongoing geopolitical tensions. These events have underscored the urgent need for a robust regulatory framework that ensures the uninterrupted availability of essential medicines. The CMA is poised to address these vulnerabilities by implementing measures that strengthen supply chain integrity and promote proactive risk management strategies.
The implications of this agreement are far-reaching for stakeholders across the pharmaceutical sector, particularly in regulatory affairs, quality assurance, and supply chain management. By fostering a more secure environment for critical medicines, the CMA not only aims to safeguard public health but also to bolster confidence among B2B professionals in the pharmaceutical industry.
Use the database as your supply chain compass →
